RSS | Login | Register

BC ORIGINAL FORMULA

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare BC ORIGINAL FORMULA to:

Generic Name for BC ORIGINAL FORMULA

Aspirin 650mg, caffeine 33.3mg, salicylamide 195mg; per powder; contains potassium 55mg/powder.

Legal Classification:

OTC

Pharmacological Class for BC ORIGINAL FORMULA

Salicylate.

Manufacturer of BC ORIGINAL FORMULA

GlaxoSmithKline Pharmaceuticals

Indications for BC ORIGINAL FORMULA

Pain. Fever.

Adult dose for BC ORIGINAL FORMULA

Place powder on tongue and follow with liquid; or may stir into glass of water or other liquids. 1 powder every 3–4 hours; max: 4 powders/24 hours.

Children's dosing for BC ORIGINAL FORMULA

Not recommended.

Contraindications for BC ORIGINAL FORMULA

NSAID allergy. Viral infection in children and teenagers. 3^rd trimester pregnancy.

Warnings/Precautions for BC ORIGINAL FORMULA

History of asthma or peptic ulcer. Severe hepatic or renal dysfunction. Bleeding disorders. Diabetes. Gout. Pregnancy. Nursing mothers: not recommended.

Interactions for BC ORIGINAL FORMULA

Potentiates anticoagulants, hypoglycemics, methotrexate, acetazolamide, valproic acid, highly protein-bound drugs. Urinary alkalinizers, antacids, corticosteroids may increase excretion. May antagonize ACE inhibitors, β-blockers, diuretics, uricosurics. Increased bleeding risk with NSAIDs or chronic, heavy alcohol use. NSAIDs increase risk of renal dysfunction. Additive effects with other caffeine-containing products.

Adverse Reactions for BC ORIGINAL FORMULA

GI upset/bleed, prolonged bleeding time, anaphylaxis, salicylism.

How is BC ORIGINAL FORMULA supplied?

Powder—2, 6, 18, 24, 50

Related Disease:

Pain, general~nonnarcotics

Phase 2 study of SB-509 for diabetic neuropathy (DN)

July 01, 2010

Sangamo BioSciences announced positive Phase 2 data from its ZFP Therapeutic program to develop SB-509 as a treatment for diabetic neuropathy (DN).

McNeil Consumer Healthcare product supply update

June 25, 2010

McNeil Consumer Healthcare announced that it does not anticipate having sources of supply for most of the products that were produced at its Fort Washington, Pennsylvania manufacturing facility before the end of 2010.

Rybix ODT launched for moderate to moderately severe pain

June 18, 2010

Victory Pharma announced that it has launched Rybix ODT (tramadol HCl, orally disintegrating tablets) for the management of moderate to moderately severe pain in patients ≥16 years of age.

McNeil recalls Benadryl Allergy Ultratab and Extra Strength Tylenol Rapid Release Gels

June 16, 2010

McNeil Consumer Healthcare has expanded its January 15, 2010 recall to include four lots of Benadryl Allergy (diphenhydramine) Ultratab Tablets and one lot of Extra Strength Tylenol (acetaminophen) Rapid Release Gels.

CDC issues statement and recommendations regarding prescription drug misuse

June 04, 2010

The CDC announced the 2009 National Youth Risk Behavior Survey (YRBS) found that 1 in 5 high school students have ever taken a prescription drug such as OxyContin (oxycodone, from Purdue), Percocet (oxycodone/acetaminophen, from Endo), Vicodin (hydrocodone/acetaminophen, from Abbott), Adderall (mixed salts of a single-entity amphetamine product, from Shire), Ritalin (methylphenidate, from Novartis), or Xanax (alprazolam, from Pfizer), without a prescription.